This isn’t just an acceptance; it’s a strategic partnership designed to supercharge the commercialization of our clinically proven wound healing solution in the U.S. market. We’ll be collaborating with powerhouses like
Mass General Brigham (the largest hospital-based research enterprise in the U.S.) and Advanced Regenerative Manufacturing Institute (ARMI) | BioFabUSA.

This accelerator is crucial for navigating the complexities of the U.S. market. It will enable us to deliver on our promise to significantly reduce the global burden of Surgical Site Infections (SSIs) and establish U.S. production for our FDA-cleared Silverstream Gel.

Join us as we work to set a new standard of care and enhance patient outcomes worldwide! ✨